# 1st Gen Model Perrigo Company Pharmaceutical preparations

Subscribe >> Deal exit on
Aug. 22, 2017 Deal entry on
Aug. 22, 2017
0.88%Expected margin
70.59% successful of 68 deals
$77.58 Last close price
at 21-aug-2017
  • Top 20 Accuracy
  • Top 20 Return

PRGO

Model's trade recommendations 0.77% Return for period

⁣

⁣ 23.09% Annual return

⁣

⁣ $11.02B Market Cap

⁣

⁣ β 0.69  

⁣

⁣

PRGO

Model (following trade recommendations)

PRGO

Underlying stock

S&P 500

Index
Return for period 0.77%
⁣ 1.70%
⁣ 1.78%
52wk return 27.38%
⁣ -15.23%
⁣ 16.82%
52wk Range —
⁣ 66.14—97.40
⁣ 2000.54—2399.63
Sortino ratio 2.68
⁣
⁣
Sharpe ratio 1.55
⁣
⁣
Norm. RMSE 1.32%
⁣
⁣
Downside risk 7.99%
⁣
⁣
Volatility 13.81%
⁣
⁣
  • 0.64 (0.83%) Div (Yield)
  • BUY Analysts consensus recommendation

Perrigo Company plc develops, manufactures and distributes healthcare products. The company operates primarily in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceutical and Active Pharmaceutical Ingredients. It also provides animal health products. The company operates primarily in the United States, the United Kingdom, Mexico, Israel, Australia, Canada, China and Latin America. Perrigo Company plc formerly known as Perrigo Company is headquartered in Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Perrigo Company (PRGO) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for PRGO model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 133M
P/E 14.98
Shares Outstanding 143M
% Held by Insiders 6.90%
% Held by Institutions 76.30%
EPS (last reported FY) $5.07
EPS (last reported Q) $1.22
EPS, estimated (last reported Q) $0.95
Total revenues $5 B
Net income $-4 B